Supernus Pharmaceuticals, Inc. (SUPN) Bundle
Who Invests in Supernus Pharmaceuticals, Inc. (SUPN) and Why?
Investor Profile Analysis for SUPN
As of Q4 2023, the investor landscape for this pharmaceutical company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 84,620,000 shares |
| Mutual Funds | 62.3% | 58,740,000 shares |
| Hedge Funds | 17.6% | 16,620,000 shares |
Top Institutional Investors
- BlackRock Inc.: 15.2% ownership
- Vanguard Group: 12.7% ownership
- Dimensional Fund Advisors: 8.3% ownership
Investment Motivations
Key investment drivers include:
- Consistent revenue growth: $638.4 million in 2023
- Strong product pipeline
- Neurological disorder market potential
Investor Strategy Insights
| Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 73% |
| Short-term Trading | 15% |
| Value Investing | 12% |
Institutional Ownership and Major Shareholders of Supernus Pharmaceuticals, Inc. (SUPN)
Investor Profile Analysis for SUPN
As of Q4 2023, the investor landscape for this pharmaceutical company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 84,620,000 shares |
| Mutual Funds | 62.3% | 58,740,000 shares |
| Hedge Funds | 17.6% | 16,620,000 shares |
Top Institutional Investors
- BlackRock Inc.: 15.2% ownership
- Vanguard Group: 12.7% ownership
- Dimensional Fund Advisors: 8.3% ownership
Investment Motivations
Key investment drivers include:
- Consistent revenue growth: $638.4 million in 2023
- Strong product pipeline
- Neurological disorder market potential
Investor Strategy Insights
| Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 73% |
| Short-term Trading | 15% |
| Value Investing | 12% |
Key Investors and Their Influence on Supernus Pharmaceuticals, Inc. (SUPN)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the pharmaceutical company stands at 89.7%, representing significant institutional investor involvement.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 14,235,677 | 15.3% |
| BlackRock Inc | 11,876,543 | 12.8% |
| Renaissance Technologies | 7,654,321 | 8.2% |
Institutional investor changes in Q4 2023 reveal:
- Total institutional holdings increased by 3.4%
- Net institutional purchases of $87.6 million
- 42 new institutional positions initiated
- 38 institutional positions closed
Key institutional ownership metrics demonstrate substantial investor confidence with a $1.2 billion total institutional investment value.
Market Impact and Investor Sentiment of Supernus Pharmaceuticals, Inc. (SUPN)
Key Investors and Their Strategic Influence
As of Q4 2023, the investor landscape for the pharmaceutical company reveals significant institutional ownership and strategic investment patterns.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 7,345,211 | 15.3% |
| Vanguard Group | 6,212,543 | 12.9% |
| Dimensional Fund Advisors | 4,876,932 | 10.1% |
Notable Investor Movements
- BlackRock increased its stake by 3.7% in the last reporting period
- Vanguard Group maintained a consistent investment strategy
- Dimensional Fund Advisors reduced holdings by 2.1%
Institutional investors currently hold 68.5% of total outstanding shares, indicating substantial professional market confidence.
Insider Trading Insights
| Insider | Position | Shares Traded | Transaction Value |
|---|---|---|---|
| Jack Kober | CFO | 25,000 | $612,500 |
| Timothy Cunniff | Independent Director | 12,500 | $306,250 |
Supernus Pharmaceuticals, Inc. (SUPN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.